FDA Orange Book · active-ingredient family
Acetaminophen; ibuprofen
Acetaminophen; ibuprofen is approved as 2 brand and 10 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:COMBOGESIC · NDA 209471
2
Brand (NDA)
10
Generics (ANDA)
3
Listed patents
1
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| COMBOGESICRLD | AFT PHARMS US | NDA 209471 | — | Mar 01, 2023 | |
| ADVIL DUAL ACTION WITH ACETAMINOPHENRLD | HALEON US HOLDINGS | NDA 211733 | — | Feb 28, 2020 |
Generic (ANDA) products (10)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ACETAMINOPHEN AND IBUPROFEN | TARO | ANDA 219053 | — | Jan 02, 2026 | |
| ACETAMINOPHEN AND IBUPROFEN | LNK INTL INC | ANDA 220126 | — | Dec 11, 2025 | |
| ACETAMINOPHEN AND IBUPROFEN | STRIDES PHARMA | ANDA 217241 | — | Jan 17, 2025 | |
| ACETAMINOPHEN AND IBUPROFEN | DR REDDYS | ANDA 218247 | — | Aug 23, 2024 | |
| ACETAMINOPHEN AND IBUPROFEN | GLENMARK PHARMS LTD | ANDA 218311 | — | Apr 26, 2024 | |
| ACETAMINOPHEN AND IBUPROFEN | AUROBINDO PHARMA LTD | ANDA 218359 | — | Mar 26, 2024 | |
| ACETAMINOPHEN AND IBUPROFEN | BIONPHARMA | ANDA 216999 | — | Aug 01, 2023 | |
| ACETAMINOPHEN AND IBUPROFEN | GRANULES | ANDA 216592 | — | Jul 13, 2023 | |
| ACETAMINOPHEN AND IBUPROFEN | MARKSANS PHARMA | ANDA 216994 | — | Jul 10, 2023 | |
| ACETAMINOPHEN AND IBUPROFEN | L PERRIGO CO | ANDA 214836 | — | Feb 28, 2023 |
Marketing exclusivity (1)
- NPNew product exclusivity (3 years)
Mar 01, 2026
4 mo ago
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 11534407 | Feb 27, 2039 | in 12 yr 11 mo | ProductU-3553 |
| 11197830 | Feb 27, 2039 | in 12 yr 11 mo | ProductU-3553 |
| 11918693 | Jul 09, 2041 | in 15 yr 3 mo | Product |
Acetaminophen; ibuprofen — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

